These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 35344138)

  • 1. The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia.
    Butt WZ; Yee JK
    Curr Atheroscler Rep; 2022 May; 24(5):379-389. PubMed ID: 35344138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancements in the Treatment of Homozygous Familial Hypercholesterolemia.
    Bajaj A; Cuchel M
    J Atheroscler Thromb; 2022 Aug; 29(8):1125-1135. PubMed ID: 35466160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia.
    Khoury E; Croteau L; Lauzière A; Gaudet D
    Future Cardiol; 2022 Jun; 18(6):507-518. PubMed ID: 35469449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapies for familial hypercholesterolemia.
    Mohamed F; Seedat F; Raal FJ
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):188-195. PubMed ID: 33278127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors.
    Pirillo A; Catapano AL; Norata GD
    Curr Atheroscler Rep; 2021 Oct; 23(12):79. PubMed ID: 34698927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evinacumab for the treatment of homozygous familial hypercholesterolemia.
    Gao Y; Zhang B; Yang J
    Expert Rev Clin Pharmacol; 2022 Feb; 15(2):139-145. PubMed ID: 35220876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias.
    Rached F; Santos RD
    Curr Cardiol Rep; 2021 Jun; 23(7):83. PubMed ID: 34081216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia.
    Pirillo A; Catapano AL
    Expert Opin Biol Ther; 2022 Jul; 22(7):813-820. PubMed ID: 35698895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia?
    Doggrell SA
    Expert Opin Biol Ther; 2021 Mar; 21(3):299-302. PubMed ID: 33295805
    [No Abstract]   [Full Text] [Related]  

  • 14. How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment.
    van den Bosch SE; Corpeleijn WE; Hutten BA; Wiegman A
    Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.
    Mohamed F; Botha TC; Raal FJ
    Curr Opin Lipidol; 2021 Aug; 32(4):213-218. PubMed ID: 33883446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Existing and emerging therapies for the treatment of familial hypercholesterolemia.
    Rosenson RS
    J Lipid Res; 2021; 62():100060. PubMed ID: 33716107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
    Robinson JG
    J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked plaque regression in homozygous familial hypercholesterolemia.
    Reeskamp LF; Nurmohamed NS; Bom MJ; Planken RN; Driessen RS; van Diemen PA; Luirink IK; Groothoff JW; Kuipers IM; Knaapen P; Stroes ESG; Wiegman A; Hovingh GK
    Atherosclerosis; 2021 Jun; 327():13-17. PubMed ID: 34004483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evinacumab for Homozygous Familial Hypercholesterolemia.
    Raal FJ; Rosenson RS; Reeskamp LF; Hovingh GK; Kastelein JJP; Rubba P; Ali S; Banerjee P; Chan KC; Gipe DA; Khilla N; Pordy R; Weinreich DM; Yancopoulos GD; Zhang Y; Gaudet D;
    N Engl J Med; 2020 Aug; 383(8):711-720. PubMed ID: 32813947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.